Skip to main content

Table 3 Cox-regression Univariate and Multivariate Analysis of Factors Affecting Mortality Rate in the CPT Group

From: The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study

Variable

Univariate

Multivariate

HR

95%CI

P-value

HR

95%CI

P-value

Sex

 Male

1.21

0.68–2.16

0.508

 Female

Ref

     

 Age

1.03

1.01–1.05

0.001

1.06

1.02–1.10

0.003

 BMI (kg/m2)

0.99

0.94–1.03

0.497

Underlying disease

 Hypertension

1.22

0.67–2.23

0.506

 Diabetes mellitus

0.67

0.36–1.22

0.187

 Chronic kidney disease

1.34

0.65–2.80

0.426

 Obesity

0.95

0.37–2.41

0.908

 Day of starting dexamethasone treatment

0.87

0.78–0.97

0.012

0.66

0.48–0.91

0.11

 Day from onset of symptoms to starting favipiravir

0.79

0.70–0.90

 < 0.001

1.11

0.80–1.54

0.548

 Receiving CPT

0.14

0.07–0.31

 < 0.001

0.26

0.08–0.79

0.018

  1. BMI body mass index, CI confidence interval, CPT convalescent plasma therapy, HR hazard ratio, Ref reference group